Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recent advances in nanoformulation development of Ritonavir, a key protease inhibitor used in the treatment of HIV-AIDS.

Expert opinion on drug delivery·2022

Same author

Multiple checkpoints of protein clearance machinery are modulated by a common microRNA, miR-4813-3p, through its putative target genes: Studies employing transgenic C. elegans model.

Biochimica et biophysica acta. Molecular cell research·2022

Same author

Novel approaches for treatment of endometrial carcinoma.

Current problems in cancer·2022

Same author

Editorial: Real World Outcomes of Lymphoma From India.

Frontiers in oncology·2022

Same author

Auxin-Inducible Degron System Reveals Temporal-Spatial Roles of HSF-1 and Its Transcriptional Program in Lifespan Assurance.

Frontiers in aging·2022

Same author

Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.

Epigenomics·2022

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Haematopoietic stem cell transplantation: current status.

¹Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. lalitaiims@yahoo.com

The National Medical Journal of India

|September 18, 2007

Summary

Haematopoietic stem cell transplantation (HSCT) offers cures for various blood disorders and cancers. Advances like reduced intensity conditioning improve outcomes, especially for older patients, by lowering graft-versus-host disease and infection risks.

More Related Videos

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Published on: February 25, 2007

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Related Experiment Videos

Last Updated: Jul 11, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Isolation and Transplantation of Hematopoietic Stem Cells (HSCs)

Published on: February 25, 2007

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Area of Science:

Hematology
Oncology
Immunology
Transplantation Medicine

Background:

Hematopoietic stem cell transplantation (HSCT) is a vital treatment for numerous malignant and non-malignant diseases.
Established HSCT protocols cure over half of patients with severe aplastic anemia, thalassemia major, and certain genetic disorders.
HSCT is also crucial for treating leukemias, lymphomas, multiple myeloma, and high-risk neuroblastoma.

Purpose of the Study:

To review the established role and evolving landscape of hematopoietic stem cell transplantation.
To discuss the major morbidities associated with HSCT, including regimen-related toxicities and graft-versus-host disease (GVHD).
To highlight advancements such as reduced intensity conditioning (RIC) and the use of peripheral blood stem cells.

Main Methods:

Review of current practices and outcomes in allogeneic and autologous HSCT.
Analysis of the impact of reduced intensity conditioning on GVHD and infection rates.
Discussion of peripheral blood stem cells as an alternative to bone marrow stem cells.

Main Results:

Allogeneic HSCT from HLA-matched donors cures a significant proportion of patients with severe inherited blood disorders.
Reduced intensity conditioning (RIC) for allogeneic HSCT lowers GVHD and infection risks, enabling treatment in older or comorbid patients.
RIC benefits patients with specific hematologic malignancies like low-grade lymphomas and chronic lymphocytic leukemia.

Conclusions:

HSCT remains a cornerstone therapy for severe hematologic conditions, both malignant and non-malignant.
RIC has expanded the applicability of allogeneic HSCT to a broader patient population.
Future research focuses on preventing GVHD while preserving graft-versus-tumor effects and optimizing autologous HSCT outcomes.